Endra Life Sciences

Q2 FY2026 EarningsQ2 FY26 results were characterized by a significant bottom-line beat and strategic shift, primarily driven by non-operating digital asset gains and a pending merger with Noble Africa. While revenue remained at zero in line with consensus, Net Income turned positive at $0.16M compared to the expected $1.6M loss, boosted by $1.7M in realized/unrealized digital asset gains. Operating expenses of $1.5M were slightly better than the $1.6M EBIT loss expectation, reflecting disciplined cost management despite a one-time surge in stock-based compensation.